Lynparza shows PFS benefit of 3.6 months in pancreatic cancer

AstraZeneca’s Lynparza olaparib has hit the minimum three-month benefit that oncologists were hoping to see in pancreatic cancer. Data presented Sunday at ASCO position the PARP inhibitor to become the first targeted agent to

Read the full 347 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE